Cancer mucosa antigens: Novel immunotherapeutic targets

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 6, 2008, Pages 749-756

  Hong, Liu ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Immunotherapy; Mucosa antigens; Tumor antigens; Tumor vaccines

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; G 17DT; GUANYLATE CYCLASE; HLA ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELANOMA ANTIGEN 1; MONOCLONAL ANTIBODY; OCCLUDIN; PROTEIN MAD2; T LYMPHOCYTE RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRIOSEPHOSPHATE ISOMERASE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; EARLY DIAGNOSIS; ESOPHAGUS CANCER; GENETIC TRANSDUCTION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH CARCINOMA; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; MUCOUS MEMBRANE; NEOPLASMS;

EID: 45849084265     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.6.749     Document Type: Review

References (64)

1. Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007;13(20):5991-4
2. Amato RJ. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther 2007;7(9):1463-9
3. Hou Y, Kavanagh B, Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol 2008;180(3):1526-34
4. Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clin Pharmacol Ther 2007;82(6):734-9
5. Waldman SA, Fortina P Surrey S, et al. Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. Future Oncol 2006;2(6):705-16
6. Piero D Cristina Mi, Chiara C, et al. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol 2003;46:33-57
7. Ottaviani S, Zhang Y, Boon T, van der Bruggen P.A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol Immunother 2005;54(12):1214-20
8. Pang KC, Wei JQ, Chen W. Dynamic quantification of MHC class I-peptide presentation to CD8+ T cells via intracellular cytokine staining. J Immunol Methods 2006;311(1-2):12-8
9. Chatterjee M, Tainsky MA. Non-traditional immunogens and their application to immunotherapy. Curr Opin Mol Ther 2008;10(1):62-7
10. Jia H, Zhou J, Ikadai H, et al. Identification of a novel gene encoding a secreted antigen 1 of Babesia gibsoni and evaluation of its use in serodiagnosis. Am J Trop Med Hyg 2006;75(5):843-50
11. Berthet FX, Coche1 T, Vinals1 C. Applied genome research in the field of human vaccines. J Biotechnol 2001;8(5):213-26
12. Elovsson S, Smailagic A, Erjefalt I, et al. Evaluation of nasal barrier dysfunction at acute- and late-phase reactions in a guinea pig model of allergic rhinitis. Vascul Pharmacol 2005;43(4):267-76
13. Zusman I. Soluble tumor-associated antigens in cancer detection, prevention and therapy. Med Sci Monit 2004;10(12):317-24
14. Malyankar UM. Tumor-associated antigens and biomarkers in cancer and immune therapy. Int Rev Immunol 2007;26(3-4):223-47
15. Lee SY, Jeoung D. The reverse proteomics for identification of tumor antigens. J Microbiol Biotechnol 2007;17(6):879-90
16. Leroy X, Buisine MP, Leteurtre E, et al. MUC1 (EMA): A key molecule of carcinogenesis? Ann Pathol 2006;26(4):257-66
17. Sette A, Newman M, Livingston B, et al. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 2002;59(6):443-51
18. Lazoura E, Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 2005;12(6):629-39
19. Apostolopoulos V, McKenzie IF, Wilson IA. Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design. Front Biosci 2001;6:1311-20
20. Baratin M, Kayibanda M, Ziol M, et al. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope. J Pept Sci 2002;8(7):327-34
21. Ma H, Kapp JA. Pepticle affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo. Cell Immunol 2001;214(1): 89-96
22. Thompson PL, Dessureault S. Tumor cell vaccines. Adv Exp Med Biol 2007;601:345-55
23. Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 2007;7(4):543-54
24. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003;4(2):104-9
25. Watanabe T, Suda T, Tsunoda T, et al. Identification of inummoglobutin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci 2005;96(8):498-506
26. Matsueda S, Takedatsu H, Sasada T, et al. New pepticle vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007;30(3):274-81
27. Lu H, Goodell V, Disis ML, Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets 2007;11(2):235-44
28. Lin T, Liang S, Meng F, et al. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer. Clin Exp Immunol 2006;144(2):319-25
29. Petersen LR, Roehrig JT. Flavivirus DNA vaccines - good science, uncertain future. J Infect Dis 2007;196(12):1721-3
30. Saif MW, Zalonis A, Syrigos K. The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Expert Opin Biol Ther 2007;7(4):493-507
31. Fernández Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005; 230(2):187-98
32. Chang GJ, Davis BS, Hunt AR, et al. Flavivirus DNA vaccines: current status and potential. Ann NY Acad Sci 2001;951:272-85
33. Laheru DA, Pardoll DM, Jaffee EM. Genes to vaccines for immunotherapy. how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther 2005;4(11):1645-52
34. Willimsky G, Blankenstein T. The adaptive immune response to sporadic cancer. Immunol Rev 2007;220:102-12
35. Frick GS, Pitari GM, Weinberg DS, et al. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 2005;5(5):701-13
36. Giannella RA, Mann EA. E. coli heat-stable enterotoxin and guanylyl cyclase C: new functions and unsuspected actions. Trans Am Clin Climatol Assoc 2003;114:67-85
37. Hong L, Qiao T, Han Y, et al. ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2. Biochem Cell Biol 2006;84(2):199-206
38. Fan D, Zhang X, Chen X, et al. Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 2005;20(3):360-5
39. Hong L, Chen Z, Zhang X, et al. Zinc ribbon domain containing 1 protein: modulator of multidrug resistance, tumorigenesis and cell cycle. Exp Oncol 2006;28(4):258-62
40. Hong L, Zhao Y, Han Y, et al. Mechanisms of growth arrest by zinc ribbon domain-containing 1 (ZNRD1) in gastric cancer cells. Carcinogenesis 2007;28(8):1622-8
41. McNeel DG. Prostate cancer antigens and vaccines, preclinical developments. Cancer Chemother Biol Response Modif 2005;22:247-61
42. Suri A. Cancer testis antigens-their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 2006;6(4):379-89
43. Karlan BY. Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? J Cell Biochem Suppl 1995;23:227-32
44. Zhang D, Chen Y, Fan D. MG7 mimotope-based DNA vaccination for gastric cancer. Expert Rev Vaccines 2006;5(2):223-31
45. Zhao Y, Jiang Y, Wang R, et al. Expression and prognostic value of MG7-Ag in patients with surgically resectable esophageal squamous cell carcinoma. Ann Surg Oncol 2007;14(9):2621-7
46. Shi R, Hong L, Wu D, et al. Enhanced immune response to gastric cancer specific antigen Pepticle by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion. Cancer Biol Ther 2005;4(2):218-24
47. Ferna'ndez-Madrid F, Tang N, Alansari H, et al. Autoantibodies to annexin XIA and other autoantigens in the diagnosis of breast cancer. Cancer Res 2004;64:5089-96
48. Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: statistical guidelines for nested case control studies. BMC Med Res Methodol Res Methodol 2002;2:4. Published online 28 February 2002 doi:10.1186/1471-2288-2-4
49. Mosca PJ, Clay TM, Morse MA, Lyerly Hk Immune monitoring. Cancer Treat Res 2005;123:369-88
50. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging th performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882-90
51. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634-5
52. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007;7(1):79-89
53. Gomes AQ, Correia DV, Silva-Santos B. Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep 2007;8(11):1024-30
54. Chouaib S. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer? Tunis Med 2005;83:7-10
55. Vieweg J, Dannull J. Technology insight: vaccine therapy for prostate cancer. Nat Clin Pract Urol 2005;2(1):44-51
56. Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and perspective. Eur J Immunol 2007;37:116-23
57. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623-33
58. Liu Y, Teige I, Bimir B, Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 2006;12(5):518-25
59. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003;171(7):3348-52
60. Witham TF, Villa L, Yang T, et al. Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol 2003;64(1-2):63-9
61. Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 2006;16(2):106-14
62. Thunberg; S, Akdis M, Akdis CA, et al. Immune regulation by CD4+CD25+ T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls. Clin Exp Allergy 2007;37(8):1127-36
63. Dermime S, Gilliam DE, Shaw DM, et al. Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 2004;1704(1):11-35
64. Rivoltini L, Castelli C, Carrabba M, et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003;171(7):3467-74